Ligand validation:6T2Y

HL9: 5-[(3~{a}~{S},4~{S},6~{a}~{R})-2-oxidanylidene-1,3,3~{a},4,6,6~{a}-hexahydrothieno[3,4-d]imidazol-4-yl]-~{N}-(1-pyridin-4-ylpiperidin-4-yl)pentanamide

HL9 is a Ligand Of Interest in 6T2Y designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6T2Y_HL9_A_302	69%	45%	0.117	0.932	0.82	1.3	-	4	0	0	100%	1
6T2Y_HL9_B_201	66%	58%	0.116	0.921	0.66	0.94	-	1	0	0	100%	1
6T31_HL9_A_201	99%	55%	0.058	0.99	0.51	1.2	-	5	0	0	100%	1
6T1E_HL9_A_405	97%	38%	0.077	0.99	1.14	1.27	3	4	0	0	100%	1
6T1K_HL9_A_201	94%	42%	0.084	0.985	0.57	1.67	-	6	1	0	100%	1
6T32_HL9_A_201	92%	43%	0.086	0.975	0.68	1.5	-	6	0	0	100%	1
6T2L_HL9_A_201	89%	54%	0.108	0.988	0.6	1.15	-	6	0	0	100%	1
6T2Z_HL9_B_201	88%	54%	0.098	0.972	0.58	1.2	-	4	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.